Age: 70.0
Sex: U
Vaccine: FLU3, TYP
Symptoms: Tinea infection
Clinical narrative: Based on additional information received on 11 May 2015, this became medically confirmed. Initial unsolicited report received from a consumer on 02 April 2015. A 71-year-old patient had received a dose of INFLUENZA VACCINE (dose, dose in series, batch number, expiry date, route and site of administration were not reported) on an unknown date (2014/2015). Medical history included diabetes and concomitant medications were not reported. The patient had been taking flu shot for the past 20 years and was never so sick. On an unknown date after vaccination the patient was so sick. Laboratory investigations and corrective treatments were not reported Documents held by sender: none. Follow-up information received from physician on 11 May 2015. A patient had received a Flu shot vaccine on 08 October 2014. The patient medical history includes, hypertensive kidney disease, diabetes mellitus type 2 causing renal disease, chronic kidney disease stage 1, nephritis and nephropathy with pathological lesion in kidney, long term current use of insulin, diabetes mellitus neuropathies, polyneuropathy in diabetes, hyperlipidemia, total body pain, vitamin d deficiency, osteopenia, colon polyps, need for pneumococcal vaccine, screening for cervical cancer, screening for colon cancer, screening for breast cancer, screening for osteoporosis, screening for eye condition, need for immunization against viral hepatitis, advice or immunization or travel, age related facial wrinkles, headache due to trauma, rhinitis, screening mammogram, rheumatoid factor positive, poor compliance, leg pain anterior, counseling about travel, pharyngitis, vaginitis, diabetes mellitus with ophthalmic manifestations, background diabetic retinopathy, diabetic cataract which were occurred on an unspecified date. The patient had received orally DIFLUCAN 150 mg tablet once a day, BETAMETHASONE/CLOTRIMAZOLE 1-0.05% 1 application to affected area externally twice a day and stop date 04 Jun 2015, orally ATORVASTATIN CALCIUM 40 mg 1 tablet once a day, orally CETIRIZINE HYDROCHLORIDE 10 mg 1 tablet as needed once a day and stop date 29 June 2015, orally DIOVAN HCT 160-12.5 mg 2 tablets once a day, subcutaneously LANTUS SOLOSTAR 100 unit/ml 80 unit in evening once a day, orally METFORMIN HCL 500 mg 1 tablet with meals twice a day, orally FLUTICASONE PROPIONATE 50 MCG/ACT a spray in each nostril nasally twice a day, orally GABAPENTIN 100 mg 1 tablet twice a day, orally MEFLOQUINE HYDROCHLORIDE 250 mg 1 tablet each week for 8 weeks and intramuscularly 25 MCG/0.5 ml Typhoid VI polysaccharide vaccine as directed once a day and also received device Lancets on an unspecified date. On an unspecified date after vaccination patient had experienced sneezing, fever, cough, rash and tinea. The patient any pre-existing physician diagnosed allergies, birth defects and medical conditions, illness at the time of vaccination and adverse event following prior vaccination were none reported. The patient laboratory investigation includes, diabetes foot exam every one year, diabetes dilated eye exam done every one year, Ankle brachial index- ultrasound Artery doppler low ext bilat done every five year, hemoglobin A1c done every one year, microalbumin random urine (w/creatinine) done every one year, mcroalb/creat ratio randm ur done every one Blood glucose monitor system as directed subcutaneously as needed, BP monitor stethoscope which results were unknown. It was reported that, relevant diagnostic test none-over the counter. At the time of this report, outcome of the event were unknown. List of the documents held by sender: yes. Follow up information received from a consumer on 23 July 2015. No new information received. List of the documents held by sender: yes.